Eli Lilly

Largest US-listed GLP-1 franchise via Mounjaro (T2D) and Zepbound (obesity). Retatrutide (triple agonist) in Phase 3; orforglipron (oral non-peptide) expected FDA decision Q2 2026. Also major diabetes, oncology, and immunology portfolios.